TP53 gene variant may lead to early onset of brain tumor

NewsGuard 100/100 Score

People with a particular gene variant may be more likely to develop brain tumors, and at an earlier age, than people without the gene, according to a study published in the January 27, 2009, print issue of Neurology, the medical journal of the American Academy of Neurology.

The study involved 254 people with brain tumors and 238 people with no cancers. All those with tumors had glioblastoma multiforme, the most common type of brain cancer. People with this type of tumor survive an average of 12 to 15 months.

Through blood samples, researchers looked at the tumor suppressor TP53 gene. This gene acts as a tumor suppressor and is involved in preventing cancer.

People younger than 45 with brain tumors were more likely to have the Pro/Pro variant of the gene than older people with brain tumors or the healthy participants. A total of 20.6 percent of the young people with brain tumors had the gene variant, compared to 6.4 percent of the older people with brain tumors and 5.9 percent of the healthy participants.

"Eventually we may be able to use this knowledge to help identify people who have a higher risk of developing brain tumors at an early age. However the risk of this population remains low, even multiplied by three or four as shown here, because these brain tumors (glioblastomas) are infrequent in young people," said study author Marc Sanson, MD, PhD, of the French National Institute of Health and Medical Research (INSERM) in Paris, France.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study identifies potential strategy to diminish the devastating impacts of traumatic brain injuries